Experts support continued use of Aranesp in certain kidney patients

10/18/2010 | Bloomberg

An FDA advisory panel voted 15-1 for continued use of Amgen's Aranesp in nondialysis patients with chronic kidney disease. The panel also voted 9-5 against lowering dosing for patients with blood hemoglobin levels less than 9 grams per deciliter. The advisers recommended further studies to determine the ideal dosing and to identify which patients benefit from Aranesp.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC